Literature DB >> 3950820

Clinical heterogeneity in cobalamin C variant of combined homocystinuria and methylmalonic aciduria.

G A Mitchell, D Watkins, S B Melançon, D S Rosenblatt, G Geoffroy, J Orquin, M B Homsy, L Dallaire.   

Abstract

We describe two patients with methylmalonic aciduria and homocystinuria (Cbl C). The disorder was not diagnosed in patient 1 until 4 1/2 years of age; he had a history of fatigue, anorexia, delirium, and spasticity. Moderate megaloblastic bone marrow changes were observed, and there was hyperreflexia of the lower limbs. His condition improved clinically with hydroxycobalamin therapy. Patient 2 was hospitalized at 6 weeks of age because of lethargy and poor feeding. She was found to have macrocytosis. Despite an initial good clinical response to hydroxycobalamin, she developed a striking pigmentary retinopathy. Methylmalonic aciduria persisted in both patients, and homocystinuria persisted in patient 1 despite therapy. The diagnosis of Cbl C disease has been confirmed in both patients by biochemical studies of cultured fibroblasts, including complementation studies. The differences in age of onset and clinical findings together with the similar biochemical findings in these two patients demonstrate the heterogeneity of phenotypic expression in patients with apparently identical abnormalities of vitamin B12 metabolism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950820     DOI: 10.1016/s0022-3476(86)80882-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

1.  The association of protein-losing enteropathy with cobalamin C defect.

Authors:  C Ellaway; J Christodoulou; R Kamath; K Carpenter; B Wilcken
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

2.  The proteome of cblC defect: in vivo elucidation of altered cellular pathways in humans.

Authors:  Marianna Caterino; Anna Pastore; Maria Grazia Strozziero; Gianna Di Giovamberardino; Esther Imperlini; Emanuela Scolamiero; Laura Ingenito; Sara Boenzi; Ferdinando Ceravolo; Diego Martinelli; Carlo Dionisi-Vici; Margherita Ruoppolo
Journal:  J Inherit Metab Dis       Date:  2015-01-14       Impact factor: 4.982

3.  Progressive neurological deterioration and MRI changes in cblC methylmalonic acidaemia treated with hydroxocobalamin.

Authors:  G M Enns; A J Barkovich; D S Rosenblatt; D R Fredrick; K Weisiger; C Ohnstad; S Packman
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

Review 4.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes.

Authors:  Nuria Carrillo-Carrasco; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 5.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management.

Authors:  Nuria Carrillo-Carrasco; Randy J Chandler; Charles P Venditti
Journal:  J Inherit Metab Dis       Date:  2011-07-12       Impact factor: 4.982

Review 6.  Hyperhomocysteinaemia; with reference to its neuroradiological aspects.

Authors:  M van den Berg; M S van der Knaap; G H Boers; C D Stehouwer; J A Rauwerda; J Valk
Journal:  Neuroradiology       Date:  1995-07       Impact factor: 2.804

7.  Treatment of cobalamin C (cblC) deficiency during pregnancy.

Authors:  Catherine Brunel-Guitton; Teresa Costa; Grant A Mitchell; Marie Lambert
Journal:  J Inherit Metab Dis       Date:  2010-09-10       Impact factor: 4.982

8.  Cobalamin C Deficiency Shows a Rapidly Progressing Maculopathy With Severe Photoreceptor and Ganglion Cell Loss.

Authors:  Lucas Bonafede; Can H Ficicioglu; Leona Serrano; Grace Han; Jessica I W Morgan; Monte D Mills; Brian J Forbes; Stefanie L Davidson; Gil Binenbaum; Paige B Kaplan; Charles W Nichols; Patrick Verloo; Bart P Leroy; Albert M Maguire; Tomas S Aleman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

9.  Methylmalonic aciduria with homocystinuria: biochemical studies, treatment, and clinical course of a Cbl-C patient.

Authors:  A Ribes; P Briones; M A Vilaseca; M Lluch; M Rodes; A Maya; J Campistol; P Pascual; T Suormala; R Baumgartner
Journal:  Eur J Pediatr       Date:  1990-03       Impact factor: 3.183

10.  Hydroxocobalamin dose escalation improves metabolic control in cblC.

Authors:  N Carrillo-Carrasco; J Sloan; D Valle; A Hamosh; C P Venditti
Journal:  J Inherit Metab Dis       Date:  2009-10-10       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.